Indications
Mayzent is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.
Composition
- Active substance
- siponimod fumaric acid
- International name (INN)
- siponimod
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Mayzent
- Active substance
- siponimod fumaric acid
- ATC code
- L04
- Therapeutic area
- Multiple Sclerosis, Relapsing-Remitting
- Marketing authorisation holder